UY39204A - Formulaciones farmacéuticas de acetato de abiraterona y niraparib - Google Patents
Formulaciones farmacéuticas de acetato de abiraterona y niraparibInfo
- Publication number
- UY39204A UY39204A UY0001039204A UY39204A UY39204A UY 39204 A UY39204 A UY 39204A UY 0001039204 A UY0001039204 A UY 0001039204A UY 39204 A UY39204 A UY 39204A UY 39204 A UY39204 A UY 39204A
- Authority
- UY
- Uruguay
- Prior art keywords
- niraparib
- abiraterone acetate
- pharmaceutical formulations
- dose
- combinations
- Prior art date
Links
- 229960004103 abiraterone acetate Drugs 0.000 title abstract 3
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title abstract 3
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title abstract 3
- 229950011068 niraparib Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 229940000425 combination drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20173749 | 2020-05-08 | ||
| US202163142919P | 2021-01-28 | 2021-01-28 | |
| US202163174282P | 2021-04-13 | 2021-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39204A true UY39204A (es) | 2021-11-30 |
Family
ID=75888052
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039204A UY39204A (es) | 2020-05-08 | 2021-05-07 | Formulaciones farmacéuticas de acetato de abiraterona y niraparib |
| UY0001039201A UY39201A (es) | 2020-05-08 | 2021-05-07 | Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib |
| UY0001039203A UY39203A (es) | 2020-05-08 | 2021-05-07 | Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039201A UY39201A (es) | 2020-05-08 | 2021-05-07 | Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib |
| UY0001039203A UY39203A (es) | 2020-05-08 | 2021-05-07 | Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20230226080A1 (https=) |
| EP (3) | EP4146210A1 (https=) |
| JP (3) | JP2023524808A (https=) |
| KR (3) | KR20230008780A (https=) |
| CN (3) | CN115515584A (https=) |
| AU (5) | AU2021267146B2 (https=) |
| BR (3) | BR112022021732A2 (https=) |
| CA (3) | CA3177123A1 (https=) |
| CR (1) | CR20220588A (https=) |
| EC (1) | ECSP22085983A (https=) |
| IL (3) | IL297984B2 (https=) |
| JO (3) | JOP20220294A1 (https=) |
| MX (3) | MX2022014003A (https=) |
| PE (1) | PE20230830A1 (https=) |
| PH (3) | PH12022553029A1 (https=) |
| TW (3) | TWI905184B (https=) |
| UA (1) | UA130040C2 (https=) |
| UY (3) | UY39204A (https=) |
| WO (3) | WO2021224467A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243120A1 (en) * | 2022-02-04 | 2023-08-10 | Janssen Pharmaceutica Nv | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and changes in hormone receptor function (HRF) |
| WO2025027138A1 (en) * | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2132449C (en) | 1992-03-31 | 2002-09-10 | Susan E. Barrie | 17 - substituted steroids useful in cancer treatment |
| JP2003104888A (ja) * | 2001-09-28 | 2003-04-09 | Taiyo Yakuhin Kogyo Kk | ジヒドロピリジン誘導体の錠剤 |
| BRPI0719236A2 (pt) * | 2006-10-13 | 2014-07-08 | Janssen Pharmaceutica Nv | Composições de carbamato de fenilalquila |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| CN102026628A (zh) * | 2008-02-15 | 2011-04-20 | 太阳医药高级研发有限公司 | 具有降低崩裂效果的口服控释片剂 |
| CA2808501A1 (en) * | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| CN102743393A (zh) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | 一种含有醋酸阿比特龙的药物组合物及制备工艺 |
| HK1213197A1 (zh) * | 2013-03-04 | 2016-06-30 | Vtv治疗有限责任公司 | 包括葡糖激酶活化劑的固體組合物及其製備和使用方法 |
| WO2015032873A1 (en) * | 2013-09-06 | 2015-03-12 | Synthon B.V. | High-load pharmaceutical compositions comprising abiraterone acetate |
| EP3160450A1 (en) * | 2014-06-30 | 2017-05-03 | Galenicum Health S.L. | Stable pharmaceutical compositions in the form of immediate release tablets |
| SG11201701139YA (en) * | 2014-09-18 | 2017-03-30 | Iceutica Inc | Abiraterone acetate formulation and methods of use |
| SG11201811564QA (en) * | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| CN110944638A (zh) * | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| HUE060460T2 (hu) * | 2017-04-13 | 2023-03-28 | Janssen Pharmaceutica Nv | Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére |
| TWI843707B (zh) * | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| JOP20200072A1 (ar) * | 2017-10-11 | 2020-04-29 | Janssen Oncology Inc | طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين |
| CA3098208A1 (en) * | 2018-04-26 | 2019-10-31 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
| CN113166071B (zh) | 2018-10-03 | 2025-03-21 | 特沙诺有限公司 | 尼拉帕利盐 |
-
2021
- 2021-05-07 TW TW110116507A patent/TWI905184B/zh active
- 2021-05-07 KR KR1020227042483A patent/KR20230008780A/ko active Pending
- 2021-05-07 UY UY0001039204A patent/UY39204A/es unknown
- 2021-05-07 BR BR112022021732A patent/BR112022021732A2/pt unknown
- 2021-05-07 TW TW110116509A patent/TWI894266B/zh active
- 2021-05-07 IL IL297984A patent/IL297984B2/en unknown
- 2021-05-07 PH PH1/2022/553029A patent/PH12022553029A1/en unknown
- 2021-05-07 MX MX2022014003A patent/MX2022014003A/es unknown
- 2021-05-07 JP JP2022567542A patent/JP2023524808A/ja active Pending
- 2021-05-07 WO PCT/EP2021/062180 patent/WO2021224467A1/en not_active Ceased
- 2021-05-07 WO PCT/EP2021/062186 patent/WO2021224469A1/en not_active Ceased
- 2021-05-07 US US17/998,202 patent/US20230226080A1/en active Pending
- 2021-05-07 EP EP21725098.4A patent/EP4146210A1/en active Pending
- 2021-05-07 AU AU2021267146A patent/AU2021267146B2/en active Active
- 2021-05-07 BR BR112022022590A patent/BR112022022590A2/pt active IP Right Grant
- 2021-05-07 CN CN202180033488.6A patent/CN115515584A/zh active Pending
- 2021-05-07 UY UY0001039201A patent/UY39201A/es unknown
- 2021-05-07 IL IL297991A patent/IL297991A/en unknown
- 2021-05-07 US US17/998,198 patent/US20230218640A1/en active Pending
- 2021-05-07 CA CA3177123A patent/CA3177123A1/en active Pending
- 2021-05-07 AU AU2021269115A patent/AU2021269115A1/en active Pending
- 2021-05-07 CA CA3177137A patent/CA3177137A1/en active Pending
- 2021-05-07 CN CN202180033482.9A patent/CN115515583A/zh active Pending
- 2021-05-07 JP JP2022567447A patent/JP2023525026A/ja active Pending
- 2021-05-07 UY UY0001039203A patent/UY39203A/es unknown
- 2021-05-07 JP JP2022567451A patent/JP2023524794A/ja active Pending
- 2021-05-07 PH PH1/2022/553013A patent/PH12022553013A1/en unknown
- 2021-05-07 EP EP21725101.6A patent/EP4146211A1/en active Pending
- 2021-05-07 UA UAA202204571A patent/UA130040C2/uk unknown
- 2021-05-07 EP EP21724665.1A patent/EP4146209A1/en active Pending
- 2021-05-07 PE PE2022002554A patent/PE20230830A1/es unknown
- 2021-05-07 MX MX2022014005A patent/MX2022014005A/es unknown
- 2021-05-07 IL IL297990A patent/IL297990A/en unknown
- 2021-05-07 PH PH1/2022/553030A patent/PH12022553030A1/en unknown
- 2021-05-07 CN CN202180033483.3A patent/CN115551506A/zh active Pending
- 2021-05-07 KR KR1020227042489A patent/KR20230008782A/ko active Pending
- 2021-05-07 MX MX2022014004A patent/MX2022014004A/es unknown
- 2021-05-07 CA CA3177094A patent/CA3177094A1/en active Pending
- 2021-05-07 WO PCT/EP2021/062188 patent/WO2021224471A1/en not_active Ceased
- 2021-05-07 BR BR112022022534A patent/BR112022022534A2/pt active IP Right Grant
- 2021-05-07 TW TW110116506A patent/TW202207925A/zh unknown
- 2021-05-07 AU AU2021266409A patent/AU2021266409A1/en active Pending
- 2021-05-07 KR KR1020227042495A patent/KR20230008783A/ko active Pending
- 2021-05-07 US US17/998,204 patent/US20230226081A1/en active Pending
- 2021-05-07 CR CR20220588A patent/CR20220588A/es unknown
-
2022
- 2022-11-01 JO JOJO/P/2022/0294A patent/JOP20220294A1/ar unknown
- 2022-11-01 JO JOJO/P/2022/0288A patent/JOP20220288A1/ar unknown
- 2022-11-01 JO JOJO/P/2022/0292A patent/JOP20220292A1/ar unknown
- 2022-11-08 EC ECSENADI202285983A patent/ECSP22085983A/es unknown
-
2025
- 2025-12-11 US US19/415,909 patent/US20260097048A1/en active Pending
-
2026
- 2026-03-23 AU AU2026202227A patent/AU2026202227A1/en active Pending
- 2026-03-25 AU AU2026202283A patent/AU2026202283A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| NI201900105A (es) | Terapia combinada para el cáncer de próstata | |
| PE20191303A1 (es) | Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2 | |
| MX2018004177A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| ECSP22085983A (es) | Formulaciones farmacéuticas de acetato de abiraterona y niraparib | |
| MX2020004516A (es) | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas. | |
| EP4552698A3 (en) | Methods of treating prostate cancer | |
| MX2021012449A (es) | Metodo para tratar tumores. | |
| CY1124280T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| CY1122508T1 (el) | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου | |
| MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
| FR3096259B1 (fr) | conjugués anticorps-médicament et leur utilisation en thérapie | |
| MX2023006087A (es) | Formulaciones liofilizadas de tegavivint. | |
| MX2020003830A (es) | Métodos para tratar el cáncer de próstata mediante la administración de acetato de abiraterona más prednisona con terapia de privación de andrógenos. | |
| MX2018012392A (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
| AR112531A1 (es) | Tratamiento de cáncer usando una cepa de blautia | |
| MX2024012392A (es) | Terapia combinada para el tratamiento del cancer | |
| MX2021001081A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| MX2024012369A (es) | Terapia combinada para el tratamiento del cancer | |
| PL425356A1 (pl) | Zastosowanie α,β dihydroksantohumolu |